Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974968 | 0.85 | PLK1 (0.55) | SPHK1ALDH1A1 | |
| SCHEMBL1976563 | 0.82 | ALDH1A1 (0.46) | EPHX2CTSLCTSBCTSSSPHK1 | |
| SCHEMBL1976788 | 0.81 | SMN1; SMN2 (0.55) | EPHX2SPHK1ALDH1A1 | |
| SCHEMBL1981191 | 0.81 | DGAT2 (0.53) | EPHX2SPHK1ALDH1A1 | |
| SCHEMBL1992821 | 0.81 | ALOX15 (0.50) | SPHK1 | |
| SCHEMBL1740344 | 0.81 | SMN1; SMN2 (0.50) | CTSLALDH1A1 | |
| SCHEMBL19075751 | 0.77 | PDE4D (0.45) | EPHX2HRH3 | |
| SCHEMBL19083723 | 0.76 | PDE4D (0.53) | EPHX2 | |
| SCHEMBL10184963 | 0.75 | HRH3 (0.43) | EPHX2HRH3ALDH1A1 | |
| SCHEMBL10184858 | 0.75 | NPC1 (0.52) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509981-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | LILLY CO ELI (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2509981-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | LILLY CO ELI (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8299061-B2 | Inhibitors of diacylglycerol acyltransferase | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299061-B2 | Inhibitors of diacylglycerol acyltransferase | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2509981-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Eli Lilly and Company (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2011071840-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071840-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT1, DGAT2, LCAT | EPHX2 950/4885CTSL 4528/4885CTSB 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.